ROCKET PHARMACEUTICALS INC (RCKT)
Health Care · Biotechnology (Gene Therapy) · NASDAQ
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
What ROCKET PHARMACEUTICALS INC does
Rocket Pharmaceuticals is a gene therapy company developing advanced therapy medical products (ATMPs) using adeno-associated virus (AAV) and lentiviral vector (LV) technologies to treat rare genetic and cardiac diseases. The company's pipeline includes candidates for conditions such as fanconi anemia, leukocyte adhesion deficiency, lysosomal storage disorders, arrhythmogenic cardiomyopathy, dilated cardiomyopathy, and other rare monogenic disorders. Rocket acquired Renovacor in December 2022 to expand its gene therapy capabilities in cardiac disease.
Themes: gene therapy, rare genetic diseases, rare blood disorders, cardiac gene therapy, lysosomal storage disorders, orphan diseases
Fundamentals
- Price$3.51 as of 2026-08-21 close
- Market cap$385M as of 2026-08-21
- 1-year return-5.9% 2025-08-21 close $3.73 → 2026-08-21 close $3.51
- P/En/a earnings data not available
- ROE-5.8% as of 2026-08-24
- Debt / equity0.06 as of 2026-08-24
- Beta0.45 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How RCKT compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ROCKET PHARMACEUTICALS INC looks technically
ROCKET PHARMACEUTICALS INC (RCKT) is trading 1.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 53 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 35.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 1.6% below its 200-day average, the long-term trend line — a long-term downtrend | -1.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.43 | $3.43 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.57 | $3.57 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.71. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 53 trading days ago — a "death cross", a bearish long-term signal | 53 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend) | 10.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.4 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($3.27 to $3.71) — its "stochastic" reading is 55 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 54.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.45 | $5.45 |
|---|---|---|
| From the 52-week high | it is 35.6% below its 52-week high (its highest price of the past year) | -35.6% |
| Above the 52-week low | it is 38.7% above its 52-week low (its lowest price of the past year) | +38.7% |
| Below the 52-week high | it is 35.6% below its highest point of the past year | 35.6% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $77.80 (set on 2015-07-24) | $77.80 |
| Given back of the 52-week move | over the past year its closes ranged ($2.66 to $5.30), and it has recovered roughly a third of its fall from last year’s high — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.29 to $4.38. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.2% |
| From the all-time high | it is 95.5% below its all-time high | -95.5% |
| Nearest price level | it is trading 1.7% above a support level at $3.45 — a price it turned at twice since 2025-09-24, most recently on 2026-01-20. Since 2024-08-21 it has 5 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.7% |
| All-time low | its lowest closing price on record is $2.19 (set on 2025-05-27) | $2.19 |
| Above the all-time low | it is 60.3% above its all-time low | +60.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 85% of it) | 15th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1954 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1954 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.08 and $3.73 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.08 – $3.40 – $3.73 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.6% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges below its 200-day average price (1.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.1% above the previous close 2 sessions ago and has not traded back through the level it left behind at 3.34 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.1% |
| Gap filled | a 2.1% gap down opened on 2026-08-18 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.9 percentage points (the stock gained 3.2% while the market gained 2.3%) | +0.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 9.8 percentage points (the stock gained 12.9% while the market gained 3.1%) | +9.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 18.2 percentage points (the stock lost 7.1% while the market gained 11.1%) | -18.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 26.4 percentage points (the stock lost 5.9% while the market gained 20.5%) | -26.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 6.2% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.73 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -5.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $3.48 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +0.8% |
Price levels it has turned at before
RCKT last closed at $3.51 on 2026-08-21. Since 2024-08-21 it has turned at 5 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.45 | Support | 1.7% below the last close | turned there twice · 2025-09-24 to 2026-01-20 |
| $3.63 | Resistance | 3.3% above the last close | turned there three times · 2025-12-11 to 2026-06-23 |
| $3.35 | Support | 4.6% below the last close | turned there four times · 2025-06-09 to 2026-04-29 |
| $3.09 | Support | 12.0% below the last close | turned there twice · 2025-10-07 to 2026-06-26 |
| $4.08 | Resistance | 16.2% above the last close | turned there four times · 2025-08-20 to 2026-04-17 |
| $4.53 | Resistance | 29.1% above the last close | turned there twice · 2025-04-09 to 2025-10-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.71.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.61 and $2.41 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.71.
This reading has stood for 5 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.36 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$8.84 range $3.00 – $15.00; median $10.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RCKT
- Consensus EPS estimate$0.2662 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development and regulatory risk: success in early-stage studies may not translate to later-stage success, and the company may not obtain FDA approval for its product candidates on the anticipated timeline or at all","Capital requirements and funding risk: as a loss-making development-stage biotech company, Rocket anticipates continued operating losses and may need additional capital to fund R&D, potentially limiting its ability to advance programs if funding is unavailable","Manufacturing and commercialization risk: novel gene therapy manufacturing requires significant cGMP infrastructure and expertise, and the company has limited sales and marketing capabilities which it may need to build or partner to commercialize products"]
What changed in the latest 10-Q
AI-assisted comparison of RCKT's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to annual report on Form 10-K filed on February 26, 2026 (newer filing, 2026-05-07)
- Mention of KRESLADI FDA accelerated approval in March 2026 for treatment of severe LAD-I in pediatric patients without suitable HLA-matched sibling donor
- Description of commercial readiness activities including treatment center onboarding, supply chain preparation, and vein-to-vein logistics coordination
- Statement that Company does not expect KRESLADI to generate material revenue in the near term
- Disclosure of PRV award in connection with KRESLADI approval and definitive agreement to sell PRV for $180 million in April 2026
- Reference to focused commercial strategy for KRESLADI scaled to ultra-rare patient population
- Revised near-term focus bullet stating 'Advancing our first-in-class product candidates targeting monogenic cardiovascular diseases with substantial unmet need from pre-IND to registrational trials'
- Added bullet point: 'Continuing to build and scale proprietary in-house analytics, process development, and manufacturing capabilities to support clinical and commercial supply'
- Added bullet point: 'Evaluating potential strategic partnerships or other transactions for certain non-core programs to enable continued development, regulatory approval, and commercialization'
- Removed:
- Company description as 'late-stage biotechnology company' changed to 'commercial-stage biotechnology company'
- Reference to annual report on Form 10-K filed on February 27, 2025 (older filing, 2025-11-06)
- Original description of company as focused on 'rare and often fatal diseases with a high unmet medical need'
- Original multi-platform description spanning 'cardiac and hematologic indications'
- Original 'Our Strategy' section header and its introductory text about bringing hope through first-in-class gene therapies
- Detail about expected 25% reduction in 12-month operating expenses
- Bullet point: 'Advancing our first-in-class product candidates targeting monogenic diseases with substantial unmet need'
- Bullet point: 'Building proprietary in-house analytics and manufacturing capabilities'
- Bullet point: 'Conducting registration trials for our lead programs'
- Medium- and long-term strategy bullets about submitting BLAs, expanding platform to additional indications, and pursuing FDA priority review vouchers
- Gene Therapy Overview section (text truncated in both versions but section header removed in newer version)
- Reworded:
- Company stage changed from 'late-stage' to 'commercial-stage' biotechnology company
- Strategic focus changed from spanning 'cardiac and hematologic indications' to specific focus on 'inherited cardiovascular conditions and select hematologic disorders'
- July 2025 reorganization description: added 'and pipeline prioritization initiative' and expanded explanation of the FDA CRL response submission
- Restructuring description: shifted from past tense 'implemented a reduction' to more detailed context about the initiative focusing on AAV cardiovascular platform
- Removed reference to specific 25% cost reduction target from operating expenses discussion
- Near-term focus restructured from general bullets to more specific cardiovascular-focused objectives
- Added specificity about 'monogenic cardiovascular diseases' versus generic 'monogenic diseases'
- Added detailed description of manufacturing and supply chain building as continuation rather than new initiative
- Notes:
- Both text versions are truncated at the end (incomplete sentence starting with 'In th' in newer version and 'We are developi' in older version), limiting full comparison of later sections
- The older filing's medium- and long-term strategy section was removed entirely in the newer filing rather than revised, reflecting strategic shift
- Commercial status change reflects actual FDA approval event occurring between filing dates
Risk Factors
- Added:
- Added to abbreviated terms (2026-05-07): AAV9, KCCQ-12, LVMI, Cantor, cKO, PRV, UCLB, UPC, and USPTO
- Added to forward-looking statements (2026-05-07): 'our ability to obtain additional funding to conduct our planned R&D efforts' as first bullet point
- Added to forward-looking statements (2026-05-07): 'our ability to close on the sale of our PRV pursuant to the asset purchase agreement we entered into in April 2026'
- Removed:
- Removed from abbreviated terms (older 2025-11-06): MAA (Marketing Authorization Application)
- Removed from abbreviated terms (older 2025-11-06): Offering (Equity offering of shares of common stock, which closed December 12, 2024)
- Removed from abbreviated terms (older 2025-11-06): Private Placement (Issuance of pre-funded warrants on December 12, 2024)
- Removed from abbreviated terms (older 2025-11-06): RBC (Red blood cell)
- Removed from abbreviated terms (older 2025-11-06): ECG (Electrocardiogram)
- Removed from abbreviated terms (older 2025-11-06): HLA (Human Leukocyte Antigen) - note: present in newer but definition differs
- Removed from forward-looking statements (older 2025-11-06): 'our ability to obtain additional funding to conduct our planned research and development efforts' (reordered and reworded in newer version)
- Reworded:
- Abbreviated terms: 'KCCQ' in older filing changed to 'KCCQ-12' in newer filing
- Abbreviated terms: 'Performance Stock Unit' in older changed to 'Performance-Based Restricted Stock Unit' in newer
- Abbreviated terms: ICD definition changed from 'Implantable cardiac defibrillator' (older 2025-11-06) to 'Internal Classification of Diseases' (newer 2026-05-07)
- Forward-looking statement reordered: 'our ability to obtain additional funding...' moved to first position in newer filing (2026-05-07)
- Forward-looking statement wording: 'research and development efforts' in older changed to 'R&D efforts' in newer
- Forward-looking statement: 'our ability to achieve the expected benefits of our portfolio prioritization and strategic restructuring and our estimates related to the costs and timing' (older) changed to 'including extending our cash runway, and our estimates related to the costs and timing' (newer)
- Page numbers changed: Risk Factors page reference was 44 (older) vs 43 (newer); subsequent items shifted by one page
- Notes:
- The quarterly report periods differ: March 31, 2026 (newer) vs September 30, 2025 (older)
- Text appears truncated at end of both versions, limiting complete comparison of full cautionary statements
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($144715) — 2 selling insiders
- Last 90 days0 buys · 2 sells ($144715) — 2 selling insiders
- Last 180 days0 buys · 10 sells ($419750) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-11. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RCKT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RCKT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,552,788
- Reported value $48,518,983
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RCKT had 15,495,507 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RCKT had 14.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.9 days to cover at the same settlement.
- Reported short interest (shares) 15,495,507
- Short interest (% of shares outstanding) 14.1%
- Prior settlement (shares) 16,571,867
- Reported change -6.5%
- Days to cover (reported) 11.9
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bluebird Bio (BLUE)
- Spark Therapeutics (DPST)
- Pfizer (PFE)
- Roche/Genentech
- Sesen Bio (SESN)
- Audentes Therapeutics (acquired by Astellas)
- Ultragenyx Pharmaceutical (RARE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RCKT vs…
ROCKET PHARMACEUTICALS INC is found in…
Frequently asked questions
What does ROCKET PHARMACEUTICALS INC (RCKT) do?
Rocket Pharmaceuticals is a gene therapy company developing advanced therapy medical products (ATMPs) using adeno-associated virus (AAV) and lentiviral vector (LV) technologies to treat rare genetic and cardiac diseases. The company's pipeline includes candidates for conditions such as fanconi anemia, leukocyte adhesion deficiency, lysosomal storage disorders, arrhythmogenic cardiomyopathy, dilated cardiomyopathy, and other rare monogenic disorders.
What sector is ROCKET PHARMACEUTICALS INC (RCKT) in?
ROCKET PHARMACEUTICALS INC (RCKT) is classified in the Health Care sector. Its industry is Biotechnology (Gene Therapy). It trades on NASDAQ.
Who are ROCKET PHARMACEUTICALS INC's (RCKT) competitors?
Notable peers of ROCKET PHARMACEUTICALS INC (RCKT) include Bluebird Bio, Spark Therapeutics, Pfizer, Roche/Genentech and Sesen Bio. This peer set is informational only — not financial advice.
Is ROCKET PHARMACEUTICALS INC (RCKT) overbought or oversold right now?
ROCKET PHARMACEUTICALS INC (RCKT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RCKT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.